Replay

Today we announce that, together with The University of Texas MD Anderson Cancer Center, we have received FDA clearance for the IND application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for patients with relapsed/refractory #AcuteMyeloidLeukemia, and #MyelodysplasticSyndromes. This new cell therapy candidate expands the growing pipeline of ‘off-the-shelf’ engineered TCR-NK therapies being developed by #Syena, our oncology-focused engineered cell therapy product company, co-founded by Replay and MD Anderson with scientific co-founder Professor Katy Rezvani, M.D., Ph.D. The PRAME program complements the existing NY-ESO-1 targeted programs in myeloma and sarcoma. The phase 1/2 study is expected to commence in Q3 2024. Learn more in today’s announcement here: https://lnkd.in/ex-GK88h #GenomicMedicine #Oncology #CellTherapy #News #FDA #TCRNK #Hematology

Listen to our Executive Chairman, President, and Co-Founder Adrian Woolfson and Chief Executive Officer and Co-Founder, Lachlan MacKinnon on the BIOS podcast where they recount Replay’s story and detail the Company’s unique hub-and-spoke business model. Find out more about what the future holds for the Company, and more broadly, for genomic medicine. https://lnkd.in/eXYxAsjs #genomicMedicine #genomeWriting #Oncology #Biotech

Our CEO and Co-Founder, Lachlan MacKinnon along with #Syena Co-Founder Katy Rezvani, spoke on the panel “Bench to biotech: Successfully collaborating to translate therapies from academia into biotech” at the Alliance for Cancer Gene Therapy Summit in New York City last week.   As trailblazing cell and gene companies and opinion leaders converged to celebrate ACGT’s 20 years of contribution to innovation in the field, we discussed the need to continue driving momentum and encourage collaboration to accelerate breakthroughs and ensure a future with effective cancer therapies.   Through our product company, Syena, we are pioneering next-generation cancer treatments based on TCR-NK technology, with our NY-ESO-1/IL-15 NK clinical program currently in a phase 1/2 study for relapsed or refractory multiple myeloma. Importantly, this novel approach also holds the potential to treat other blood cancers and solid tumors to help improve the lives of millions of patients worldwide.   Learn more here: https://replay.bio/   #genomicMedicine #genomeWriting #Oncology 

Following the recent announcement that the first patient has been dosed in the Phase 1/2 study of NY-ESO-1/IL-15 NK for relapsed or refractory multiple myeloma, the lead clinical program of #Syena, Replay’s oncology-focused engineered NK cell therapy product company, our Executive Chairman, President, and Co-Founder Adrian Woolfson and Chief Executive Officer, Lachlan MacKinnon sat down with Caroline Hopkins at Precision Medicine Online to discuss the significant potential #Syena’s TCR-NK approach holds in the treatment of solid tumors and blood cancers.   NY-ESO-1 TCR/IL-15 NK is the lead clinical program of #Syena, Replay’s oncology-focused product company formed together with the MD Anderson Cancer Center. Syena’s TCR-NK technology is based on the scientific discoveries of Professor Katy Rezvani, M.D., Ph.D.   Read the full article here: https://lnkd.in/ej2WFM-B  #genomicMedicine #genomeWriting #Oncology #Syena 

As March is Myeloma Action Month, it is only fitting to recognize the incredible progress in treatment options available for patients with multiple myeloma over the last twenty years. Scientific innovation has contributed to better and safer treatment options, with new modalities dramatically changing the treatment paradigm.  Despite this progress, myeloma remains a complex cancer with a vast spectrum of presentations that makes treatment challenging, and the unmet medical need is still high. According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, approximately 35,730 people living in the United States were diagnosed with multiple myeloma in 2023, and a similar number will be diagnosed in 2024. Multiple myeloma is also a cancer with the largest racial disparities in incidence and mortality, where the death rate is more than twice as high in black people than in white people.   The complexity, inaccessibility, and individuality of treatment options for multiple myeloma highlights the need for more effective and tailored treatment approaches to address unique patient needs. At Replay, the key driving factor behind the development of our TCR-NK cell therapy, NY-ESO-1/IL-15 NK, for relapsed or refractory multiple myeloma, which is currently in Phase 1 clinical trial, and other TCRs in our pipeline, is the need to have more off-the-shelf cell therapies with greater equitable access and increased safety.   We must all come together to raise awareness and be part of a global movement making an impact on those who have this blood cancer. Discover how you can be part of the movement: https://lnkd.in/dUGmQk5z #MyelomaActionMonth #genomicMedicine #genomeWriting #Oncology #Syena 

We are pleased to announce that the first patient has been dosed in the Phase 1/2 study of NY-ESO-1/IL-15 NK, an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma developed at the MD Anderson Cancer Center. NY-ESO-1 TCR/IL-15 NK is the lead clinical program of #Syena, Replay’s oncology-focused product company formed together with MD Anderson Cancer Center. The TCR-NK technology is based on the scientific discoveries of Professor Katy Rezvani, M.D., Ph.D. The study is designed to assess the safety and efficacy of NY-ESO-1/IL-15 NK in up to 44 patients. Read more here: https://lnkd.in/ebdwtPhs #genomicMedicine #genomeWriting #Oncology #Syena

Our Executive Chairman, President, and Co-Founder, Adrian Woolfson, is here in Boston, MA, at the 44th Annual Cowen Inc. Health Care Conference, and looking forward to attending the action-packed schedule of fireside chats and corporate panels.   #TDCowen #TDCowenHealthCare #CowenHealthCareConference #Biotech #GenomicMedicine #GenomeWriting  

Catch our Executive Chairman, President, and Co-Founder, Adrian Woolfson, at the World Governments Summit 2024 in Dubai this week. The #WGS2024 gathers governments, the private sector, thought leaders and international organizations to discuss how best to shape a brighter future for humanity, with topics ranging from “AI and Next Frontiers” to “Urbanization and Global Health Priorities”.   Find out more about the event here: https://lnkd.in/dZ6Ncfet   #WGS2024 #Innovation #NextGeneration 

We are celebrating the International Day of Women and Girls in Science, recognizing the vital role of women and girls in advancing science, technology, and innovation, tackling the world’s toughest health challenges and revolutionizing the treatment landscape. This day is a reminder of the importance of diversity and inclusivity in the scientific community, and we want to take this opportunity to thank and celebrate the inspirational and talented women at Replay, who are driving forward our mission of creating next generation #genomicmedicines to address some of the most challenging diseases burdening society.   #WomenAndGirlsInScience #Replay #Inspiration #WomenInStem

Yesterday was #WorldCancerDay, a global initiative that reimagines a world where millions of cancer deaths are prevented and access to treatment and care is equitable for all.   These are key goals for everyone working in oncology research. When we established our cancer-focused company, Syena, last year with MD Anderson Cancer Center, it was to transform engineered #cellTherapy – developing the next generation of treatments capable of overcoming current scientific and clinical challenges. And, importantly, expanding the reach of this technology with ‘off-the-shelf’ therapies to address a broader range of cancers. The first two #clinicalTrials of our investigational NY-ESO-1 TCR-NK cell therapy are actively recruiting patients with advanced synovial #sarcoma and myxoid/round cell #liposarcoma, and with relapsed or refractory #multipleMyeloma. We look forward to the progress of both studies and realizing the true potential of cell therapy so fewer #cancer patients are left behind.   #WorldCancerDay #CloseTheCareGap